Stephen J Atkinson

12PUBLICATIONS
54CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cheminformatics and quantitative structure-activity relationshipsGene and molecular therapyBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Dec 30, 2025
BET Isoform Selectivity through Diverse Linkers for Bivalent Inhibitors: GSK785, a BRD2/4-Selective Bivalent BET Inhibitor.

Francesco Rianjongdee, Stephen J Atkinson, Paul Bamborough

|Jan 09, 2025
Phenotype-Led Identification of IL-10 Upregulators in Human CD4+ T-cells and Elucidation of Their Pharmacology as Highly Selective CDK8/CDK19 Inhibitors.

Simon Nicolle, Mike Barker, John Barrett

|Mar 11, 2024
Development of a Series of Pyrrolopyridone MAT2A Inhibitors.

Stephen J Atkinson, Sharan K Bagal, Argyrides Argyrou

|Aug 31, 2022
A patent review of MAT2a inhibitors (2018-2021).

Stephen J Atkinson, Laura Evans, James S Scott

|Jan 07, 2022
Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.

Philip G Humphreys, Stephen J Atkinson, Paul Bamborough

|Jul 14, 2021
Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.

Simon C C Lucas, Stephen J Atkinson, Chun-Wa Chung

Pageof 2

Frequent Collaborators

8 joint publications

Alex Preston

8 joint publications

Chun-Wa Chung

8 joint publications

Emmanuel H Demont

7 joint publications

Paul Bamborough